^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug:cisplatin (DNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
12/21/2020
Excerpt:
Nasopharyngeal carcinoma: Recommendations...stage III and IVA disease are treated by CRT...the standard agent used is cisplatin.
DOI:
10.1016/j.annonc.2020.12.007
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Single Agents…Cisplatin